Kombinovana detekcija HLA-B27, ESR i CRP kao biohemijskih i imunogenetskih markera u pomoćnoj dijagnozi ankilozantnog spondilitisa

HLA-B27, ESR, and CRP in Ankylosing Spondylitis

  • Muchuan Wang Odeljenje za sportsku medicinu, Peking Jishuitan bolnica, Kapital Medicinski univerzitet
  • Siyuan Yao Odeljenje za hirurgiju kičme, Peking Shijitan bolnica povezana sa Capital Medical Universiti
  • Chengao Gao Odeljenje za ortopedsku hirurgiju, Peking unija Medicinski fakultet bolnica
  • Yipeng Wang Odeljenje za ortopedsku hirurgiju, Peking unija Medicinski fakultet bolnica
DOI: https://doi.org/10.5937/jomb0-61518

Sažetak


Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease in which early diagnosis is often challenging due to atypical clinical manifestations. Laboratory biomarkers such as human leukocyte antigen-B27 (HLA-B27), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) play an essential role in diagnostic evaluation.

Methods: A total of 120 AS patients and 100 healthy controls were enrolled. Venous blood samples were analyzed for HLA-B27 (flow cytometry), ESR (Westergren method), and CRP (immunoturbidimetry). The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was assessed, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.

Results: HLA-B27 positivity was significantly higher in the AS group than in controls (92.5% vs. 5.0%, P<0.001). Both ESR and CRP levels were markedly elevated in AS patients and showed a progressive increase with higher BASDAI scores (P<0.05). ROC analysis demonstrated superior diagnostic efficacy of combined HLA-B27, ESR, and CRP detection (AUC=1.000, sensitivity 97.2%, specificity 93.3%) compared with single markers.

Conclusion: The combined detection of HLA-B27, ESR, and CRP provides a reliable laboratory-based diagnostic approach for ankylosing spondylitis, enhancing accuracy and clinical applicability. These findings highlight the importance of integrating biochemical and immunogenetic markers into routine diagnostic practice.

Reference

1. Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clin Rheumatol 2021; 40(8): 3079-93.
2. Pasaran E, Diaconu AE, Oancea C, Balanescu A, Aurelian SM, Homentcovschi C. An Actual Insight into the Pathogenic Pathways of Ankylosing Spondylitis. Curr Issues Mol Biol 2024; 46(11): 12800-12.
3. Kim SH, Lee S. Updates on ankylosing spondylitis: pathogenesis and therapeutic agents. J Rheumat Dis 2023; 30(4): 220-33.
4. Choufani M, Ermann J. Updating the 2019 ACR/SAA/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (SPARTAN 2024 Annual Meeting Proceedings). Curr Rheumatol Rep 2024; 27(1): 8.
5. Wei JC, Hung K, Hsu Y, Wong R, Huang C, Jan M, et al. Genetic polymorphisms of stromal interaction molecule 1 associated with the erythrocyte sedimentation rate and C-reactive protein in HLA-B27 positive ankylosing spondylitis patients. Plos One 2012; 7(12): e49698.
6. Khan MA, Yong S, Wei JC. Ankylosing spondylitis: History, epidemiology, and HLA-B27. Int J Rheum Dis 2023; 26(3): 413-4.
7. Garrido-Mesa J, Brown MA. T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis. Curr Rheumatol Rep 2022; 24(12): 398-410.
8. Bulut Gokten D, Mercan R, Kurtuldu B, Tozkir H. Low Frequency of HLA-B27 in Ankylosing Spondylitis Patients from Turkey: Insights from the Thrace Region. Med Sci Monitor 2025; 31: e948449.
9. Cao X, Zhang Y, Xiao Z, Peng J. Efficacy and safety of acupuncture combined with Western medicine in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Medicine 2025; 104(21): e42468.
10. Massignan A, Knabben MM, Da Silva TB, Hohgraefe Neto G. Review of the updated definitions and concepts of spinal lesions in axial spondyloarthritis. Skeletal Radiol 2024:
11. Xu W, Wang D, Zhao M, Huang A. An updated advancement of bifunctional IL-27 in inflammatory autoimmune diseases. Front Immunol 2024; 15: 1366377.
12. Long F, Wang T, Li Q, Xiong Y, Zeng Y. Association between Klebsiella pneumoniae and ankylosing spondylitis: A systematic review and meta-analysis. Int J Rheum Dis 2022; 25(4): 422-32.
13. Kim HW, Kim EH, Lee M, Jung I, Ahn SS. Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-alpha inhibitors: a nationwide nested case-control analysis. Clin Exp Rheumatol 2023; 41(7): 1491-9.
14. Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol 2022; 18(4): 205-16.
15. Riis A, Olesen JL, Thomsen JL. Early differential diagnosis of ankylosing spondylitis among patients with low back pain in primary care. Bmc Fam Pract 2020; 21(1): 90.
16. Khan MA. HLA-B*27 and Ankylosing Spondylitis: 50 Years of Insights and Discoveries. Curr Rheumatol Rep 2023; 25(12): 327-40.
17. Khan MA, Braun WE, Kushner I, Grecek DE, Muir WA, Steinberg AG. HLA B27 in Ankylosing Spondylitis: Differences in Frequency and Relative Risk in American Blacks and Caucasians. J Rheumatol 2023; 50(1): 39-43.
18. Kasapoglu Aksoy M, Altan L, Gorukmez O, Guner A, Ayar K. The relationship between CRP gene polymorphism (rs2794521, rs3091244), ASDAS-CRP and ASDAS-ESR in ankylosing spondylitis. Mod Rheumatol 2020; 30(4): 715-20.
19. Rapapa KA, Deng Y, Peng Y, Ni J, Pan F. The association and clinical significance of hematological biomarkers in ankylosing spondylitis. Sci Rep-Uk 2025; 15(1): 15755.
Objavljeno
2025/10/08
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2025 Muchuan Wang, Siyuan Yao, Chengao Gao, Yipeng Wang

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.